Litany of unknowns surface at FDA germline modification meeting

An FDA committee held a historic public meeting last week to discuss the scientific, technologic, and clinical issues related to experimental procedures that would alter the human germline.

What was most striking about the meeting was that the committee members, many of whom are scientists themselves, are so wary of the techniques at this time. Questions about efficacy and safety – in fact a litany of concerns about every aspect of these techniques – largely dominated the discussions. And although the FDA’s pre-meeting briefing document explicitly put social and ethical issues outside the scope of the discussion, a myriad of these problems also edged their way in.

Related on the SLP

With global gene editing slow down, what’s the future of ‘designer babies?’ Proceed with caution: National Academies offers ‘qualified support’ for gene editing ‘abnormal’ embryos

Genetics of IQ: At what age do various forms of intelligence peak?

‘They’ve already decided what they want studies to say’: Questioning Trump’s plan to study whether people distressed about their sex are prone to violence

Himalayan and other specialty salts are cool, but they contribute to dangerous iodine deficiency. Here’s how iodized table salt helped raise America’s IQ—and why it still matters for your health

Read the full, original story: Litany of Unknowns Surface at FDA Meeting on Germline Mitochondrial Techniques